Washington—Despite recent studies reporting its efficacy in preventing flu, particularly in children, the latest live virus candidate vaccine against influenza (FluMist, Aviron, Mountain View, Calif), faces an uphill road on its way to licensure. Some evidence for this conclusion appears in a newly published report of a workshop held in December 1998 at the Paul Ehrlich Institute in Langen, Germany (Biologicals. In press).
The workshop was attended by representatives of US and European public health agencies, regulatory authorities, academic scientists, and manufacturers, said Reinhard Kurth, MD, president of the Paul Ehrlich Institute, in an interview.
Marwick C. Merits, Flaws of Live Virus Flu Vaccine Debated. JAMA. 2000;283(14):1814-1815. doi:10.1001/jama.283.14.1814-JMN0412-3-1